The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sopheon Deployed Globally at The 3M Company

2 Jun 2021 07:00

RNS Number : 4875A
Sopheon PLC
02 June 2021
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Announces Global Deployment of Enterprise Innovation Management Solution at The 3M Company

 

3M manages its global portfolio of innovation and growth initiatives using Sopheon Accolade®

 

Sopheon has today announced that The 3M Company (NYSE: MMM) a long-standing customer of the group, is using its Accolade software for new product development throughout its global enterprise. 3M's cross-functional innovation teams rely on Sopheon Accolade to streamline processes, manage risk, optimize decision-making and accelerate time to market.

3M produces over 60,000 products under several brands and is a leader in consumer products, safety and industrial, healthcare, transportation, and electronics. 3M's deployment of Sopheon Accolade is enterprise-wide, including every division and business group across the company. This implementation involves thousands of users at all levels of the business, including research and development (R&D) scientists and researchers, manufacturing, supply chain, finance, sales and marketing, as well as commercialization managers and senior executives.

"R&D is the heartbeat of 3M," said Elizabeth Edblom, Ph.D., Director, Corporate Research & Development Global Strategy and New Growth at 3M. "Innovation is the thread that connects our four business groups to the vast amount of science conducted by the thousands of scientists and researchers we have around the world. The unprecedented enterprise-wide transparency provided by the Sopheon Accolade platform allows us to know what's going on in new product commercialization before, during and after launch. Additionally, Accolade's unique portfolio management capabilities provide business leaders with planning and performance insights required to govern the millions of dollars 3M invests in innovation. Finally, 3M is proud of our Sustainability Value Commitment for all new products - and Sopheon Accolade helps make that possible."

Accolade is Sopheon's award-winning innovation management platform that connects people, systems and information across departments and functions. This collaboration and synchronization results in trusted, timely data for faster, better and more dynamic decision making. In addition to 3M, Sopheon Accolade has proven its value to thousands of other global users, such as Honeywell, Merck KGaA, P&G, Philips, BASF, Parker Hannifin and other innovation and market leaders across a wide variety of industries.

"3M's commitment to innovation is extraordinary," said Greg Coticchia, CEO, Sopheon. "With 8,000 scientists and researchers working on 51 technology platforms in 650 different countries, it's essential that they have a global system that allows engagement and visibility among all functions. In addition to enabling the alignment of strategy and execution, the configurability of Accolade allowed 3M to deploy a system that ensures the organization remains focused on outcomes and not processes."

 

 

For further information contact:

Andy Michuda (Executive Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Edward Whiley (Corporate Finance)Alice Lane/Sunila da Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

Sopheon and Accolade are trademarks of Sopheon plc. Stage-Gate® is a registered trademark of Stage-Gate Inc.

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.  

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFIRRLILIIL
Date   Source Headline
3rd Nov 202310:15 amRNSForm 8.5 (EPT/NON-RI)
3rd Nov 20238:54 amRNSForm 8.3 - Rivomore Limited - Sopheon plc
2nd Nov 20239:34 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20233:44 pmEQSForm 8.3 - Apex Fundrock Limited : Form 8.3 Apex Fundrock Limited Re: Sopheon PLC
1st Nov 20231:55 pmRNSForm 8.3 - Sopheon plc
1st Nov 202311:23 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202310:51 amGNWForm 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
1st Nov 202310:35 amRNSForm 8.3 - Sopheon PLC
31st Oct 20231:00 pmRNSStatement re Possible Offer
24th Aug 20237:00 amRNSInterim Results
10th Jul 20237:00 amRNSAcquisition
15th Jun 20235:06 pmRNSIssue of Equity
8th Jun 20231:35 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Statement
13th Apr 20234:20 pmRNSIssue of Equity
31st Mar 20239:14 amRNSIssue of Equity
27th Mar 20234:23 pmRNSDirector Shareholdings
24th Mar 20237:00 amRNSDirector Share Purchases
23rd Mar 20237:00 amRNSFinal Results
22nd Feb 20234:59 pmRNSIssue of Equity
6th Feb 20237:00 amRNSDirectorate Change and Notice of Results
30th Jan 20237:00 amRNSTrading Update
20th Sep 202212:01 pmRNSSopheon launches Acclaim Line of SaaS Offerings
2nd Sep 202210:06 amRNSIssue of Equity
1st Sep 20227:00 amRNSNew Release of Award-winning Innovation Product
24th Aug 20227:00 amRNSInterim Results
16th Aug 20227:00 amRNSFive-year, $11.2m Enterprise Agreement
3rd Aug 202210:18 amRNSHolding(s) in Company
21st Jun 202212:20 pmRNSHolding(s) in Company
9th Jun 20222:30 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
6th Jun 20226:02 pmRNSIssue of Equity & TVR
23rd May 20227:00 amRNSDirector Dealing & Issue of Equity
18th May 20227:00 amRNSAcquisition
29th Apr 20225:12 pmRNSHolding(s) in Company
7th Apr 20227:00 amRNSNew Sopheon Software Release
1st Apr 202212:10 pmRNSDirector Shareholdings
24th Mar 20227:00 amRNSFinal Results
25th Jan 20227:00 amRNSTrading Update
17th Jan 20223:15 pmRNSIssue of Equity
20th Dec 20217:00 amRNSAcquisition and Trading Update
24th Sep 20211:52 pmRNSIssue of Equity
16th Sep 202110:00 amRNSHolding(s) in Company
13th Sep 20215:24 pmRNSIssue of Equity
31st Aug 20216:14 pmRNSDirector Shareholdings
25th Aug 20217:00 amRNSInterim Results
13th Jul 20217:00 amRNSNew Release Drives Business Transformation
23rd Jun 20217:00 amRNSSopheon Earns Authority to Operate for NAVSEA
15th Jun 20219:54 amRNSIssue of Equity
10th Jun 202111:43 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.